Location History:
- Gladbach, DE (2002)
- Bergisch Gladbach, DE (1999 - 2007)
Company Filing History:
7 out of 12,168 
2 out of 77 
1 out of 38 Years Active: 1999-2007
Title: Unveiling the Innovations of Inventor Arno Friedl from Bergisch Gladbach, DE
Introduction:
Arno Friedl, a prolific inventor hailing from Bergisch Gladbach, Germany, has left a lasting impact on the field of pharmaceuticals with his groundbreaking patents and contributions. With an impressive portfolio of 10 patents under his belt, Friedl's work has focused on developing medicaments for the treatment and prophylaxis of various neurodegenerative disorders, including Parkinson's disease and schizophrenia.
Latest Patents:
Friedl's latest patents showcase his innovative approach to developing pharmaceutical solutions:
1. Substituted Imidazotriazines: This invention introduces new substituted imidazotriazines and outlines processes for their synthesis. These compounds hold promise for the production of medicaments targeting cancer and neurodegenerative disorders.
2. Imidazotriazines for Use as Phosphodiesterase Inhibitors: Another patent by Friedl explores the use of imidazotriazines as phosphodiesterase inhibitors for the treatment of neurodegenerative disorders, particularly Parkinson's disease.
Career Highlights:
Friedl has had a distinguished career, having worked with renowned pharmaceutical companies such as Bayer AG (Bayer Aktiengesellschaft) and Bayer Healthcare AG (Bayer Healthcare Aktiengesellschaft). His tenure at these organizations has provided him with a platform to translate his innovative ideas into tangible solutions for pressing healthcare challenges.
Collaborations:
Throughout his career, Friedl has collaborated with esteemed professionals in the field. Notable coworkers include Frank Mauler and Reinhard Jork, with whom he has synergized efforts to drive forward impactful research and development projects.
Conclusion:
Inventor Arno Friedl's inventive spirit and dedication to advancing pharmaceutical science have positioned him as a key figure in the realm of neurodegenerative disorder treatments. His patent portfolio stands as a testament to his commitment to innovation and his relentless pursuit of developing novel medicaments for improving human health and well-being.